Literature DB >> 29866503

Determining the Role and Duration of the "Antibiotic Holiday" Period in Periprosthetic Joint Infection.

Timothy L Tan1, Michael M Kheir1, Alexander J Rondon1, Javad Parvizi1, Jaiben George2, Carlos A Higuera2, Noam Shohat3, Antonia F Chen1.   

Abstract

BACKGROUND: Two-stage exchange arthroplasty involves resection and reimplantation of new implants at a later stage. An antibiotic-free period is often advocated by surgeons before reimplantation. However, there is no conclusive evidence supporting the utility or duration of this practice. This study evaluated the utility and optimal duration of the antibiotic-free period before reimplantation.
METHODS: Electronic infection databases of 2 institutions were retrospectively reviewed from 2000 to 2014 to identify 785 patients who underwent 2-stage exchange arthroplasty, of which 409 were reimplanted without any surgeries between the first and second stage. Total joint arthroplasties that met the Musculoskeletal Infection Society criteria for periprosthetic joint infection (PJI) and had a minimum of 1-year follow-up were included. The antibiotic holiday period was defined as the time period off antibiotics before reimplantation. Treatment success was defined according to the Delphi consensus criteria. A multivariate analysis and Fisher exact test were performed.
RESULTS: The duration of the antibiotic-free period was not significantly associated with reinfection following reimplantation after controlling for potential confounders, including joint involvement, gender, institution, and comorbidities. However, the duration of spacer implantation was significantly associated with reinfection. Of the patients who failed treatment, 41.5% failed on antibiotics while 58.5% failed during the antibiotic-free period at a mean of 26.1 days.
CONCLUSION: The duration of an antibiotic-free period does not appear to significantly affect PJI rate after reimplantation. However, many patients fail during the antibiotic-free period. Further prospective studies are needed to determine the optimal timing of reimplantation for 2-stage exchange arthroplasty for PJI treatment.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  antibiotic-free period; exchange arthroplasty; infection; outcomes; reimplantation

Mesh:

Substances:

Year:  2018        PMID: 29866503     DOI: 10.1016/j.arth.2018.04.019

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  6 in total

1.  CORR Insights®: Synovial Cell Count Before Reimplantation Can Predict the Outcome of Patients with Periprosthetic Knee Infections Undergoing Two-stage Exchange.

Authors:  Matthew L Webb
Journal:  Clin Orthop Relat Res       Date:  2021-09-01       Impact factor: 4.755

2.  Changes in serum markers failed to predict persistent infection after two-stage exchange arthroplasty.

Authors:  Qiao Jiang; Jun Fu; Wei Chai; Li-Bo Hao; Yong-Gang Zhou; Chi Xu; Ji-Ying Chen
Journal:  J Orthop Surg Res       Date:  2020-09-04       Impact factor: 2.359

Review 3.  Periprosthetic joint infection: current concepts and outlook.

Authors:  Petra Izakovicova; Olivier Borens; Andrej Trampuz
Journal:  EFORT Open Rev       Date:  2019-07-29

Review 4.  Twenty common errors in the diagnosis and treatment of periprosthetic joint infection.

Authors:  Cheng Li; Nora Renz; Andrej Trampuz; Cristina Ojeda-Thies
Journal:  Int Orthop       Date:  2019-10-22       Impact factor: 3.075

5.  Current and Future Burden of Periprosthetic Joint Infection from National Claim Database.

Authors:  Hong Seok Kim; Jung Wee Park; Sun Young Moon; Young Kyun Lee; Yong Chan Ha; Kyung Hoi Koo
Journal:  J Korean Med Sci       Date:  2020-12-21       Impact factor: 2.153

6.  Two-stage exchange Arthroplasty is a viable treatment for Periprosthetic joint infection in inflammatory diseases.

Authors:  Qiao Jiang; Jun Fu; Wei Chai; Li-Bo Hao; Yong-Gang Zhou; Chi Xu; Ji-Ying Chen
Journal:  BMC Musculoskelet Disord       Date:  2020-10-14       Impact factor: 2.362

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.